Bangalore-based pharmaceutical company Strides Arcolab Ltd (Strides) on Wednesday announced collaboration with US pharmaceutical company Eli Lilly wherein oral and injectable cancer medicines manufactured by Strides’s injectable business unit Agila Specialties will be registered and marketed by Eli Lilly across emerging markets.
Besides, Lilly will also have the right to add additional branded generic oncology products to its portfolio in future.
Senior Vice-President of Eli Lilly Jacques Tapiero said, “This agreement will help Lilly expand its portfolio and deliver high-quality medicines to patients across emerging markets.”
Deccan Herald is on WhatsApp Channels| Join now for Breaking News & Editor's Picks